Lineage Cell Therapeutics Dirección
Dirección controles de criterios 2/4
Lineage Cell Therapeutics' CEO is Brian Culley, appointed in Sep 2018, has a tenure of 6.17 years. total yearly compensation is $2.91M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $126.32K. The average tenure of the management team and the board of directors is 3.8 years and 8 years respectively.
Información clave
Brian Culley
Chief Executive Officer (CEO)
US$2.9m
Compensación total
| Porcentaje del salario del CEO | 22.0% |
| Permanencia del CEO | 6.2yrs |
| Participación del CEO | 0.08% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 8yrs |
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$3m | US$640k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$2m | US$609k | -US$26m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$3m | US$580k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$552k | -US$21m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$773k | US$536k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$52m |
| Jun 30 2019 | n/a | n/a | US$31m |
| Mar 31 2019 | n/a | n/a | US$57m |
| Dec 31 2018 | US$3m | US$155k | -US$46m |
Compensación vs. Mercado: Brian's total compensation ($USD2.91M) is above average for companies of similar size in the US market ($USD1.48M).
Compensación vs. Ingresos: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian Culley (53 yo)
6.2yrs
Permanencia
US$2,905,130
Compensación
Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 6.2yrs | US$2.91m | 0.082% $ 126.3k | |
| CFO & Principal Financial and Accounting Officer | 2yrs | US$738.86k | 0.0056% $ 8.6k | |
| General Counsel & Company Secretary | 3.2yrs | US$1.21m | 0.0038% $ 5.9k | |
| Director of Investor Relations | no data | sin datos | sin datos | |
| Vice President of Corporate Development | less than a year | sin datos | sin datos | |
| Consultant | 3.8yrs | US$668.25k | sin datos | |
| President & CEO of OncoCyte Corporation | no data | US$654.85k | sin datos | |
| Chief Executive Officer of Cell Cure Neurosciences | no data | sin datos | sin datos | |
| Senior Director of Finance & Controller | 5.2yrs | sin datos | sin datos | |
| Vice President of Regulatory Affairs & Quality Control | 29.8yrs | US$90.00k | sin datos |
3.8yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: LCTX's management team is considered experienced (3.8 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 6.2yrs | US$2.91m | 0.082% $ 126.3k | |
| Independent Director | 5.7yrs | US$130.50k | 0.084% $ 129.5k | |
| Independent Director | 9.9yrs | US$138.00k | 0.046% $ 71.4k | |
| Independent Director | 3.5yrs | US$128.00k | 0.0053% $ 8.2k | |
| Independent Director | 15.3yrs | US$141.13k | 0.046% $ 71.5k | |
| Independent Director | 10.6yrs | US$148.00k | 0.0083% $ 12.7k | |
| Independent Chairman | 10.1yrs | US$151.13k | 0.14% $ 210.9k | |
| Independent Director | 3.6yrs | US$128.00k | 0.019% $ 28.5k |
8.0yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: LCTX's board of directors are considered experienced (8 years average tenure).